FDA — authorised 25 January 2013
- Application: NDA022426
- Marketing authorisation holder: TAKEDA PHARMS USA
- Status: supplemented
FDA authorised Alogliptin and pioglitazone on 25 January 2013
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 25 January 2013; FDA has authorised it.
TAKEDA PHARMS USA holds the US marketing authorisation.